. 2021 Aug 24;26(11):e2002–e2012. doi: 10.1002/onco.13918
© 2021 Pfizer, Inc, Premier, Inc and EMD Serono. The Oncologist published by Wiley Periodicals LLC on behalf of AlphaMed Press.
This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
Figure 5.
Average total costs by immune‐related adverse event type.